AHS 2023 | Translating migraine treatment advances into the pediatric space

The recent introduction of novel migraine medications, such as calcitonin gene-related peptide (CGRP) pathway inhibitors and ditans, is changing the treatment of migraine. However, most of the data are still limited to the adult population. Christina Szperka, MD, Children’s Hospital of Philadelphia & University of Pennsylvania, Philadelphia, PA, comments on translating migraine treatment advances into the pediatric space. Clinical trials evaluating acute and preventative treatments, specifically on primary headache in pediatric populations, are ongoing, and their results are highly anticipated. Furthermore, some non-pharmacological therapies, such as non-invasive neuromodulation devices, have indications for migraine treatment in children and adolescents. Still, substantial data from clinical trials in this patient population is yet to be available. This interview took place at the American Headache Society 2023 meeting in Austin, TX.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.